Predict your next investment

INDUSTRIAL | Basic Materials / Specialty Chemicals
kolonls.co.kr

See what CB Insights has to offer

Founded Year

2000

About Kolon Life Science

Kolon Life Science develops cell and gene therapies including Invossa, a cell-mediated gene therapy for osteoarthritis. The company is also engaged in the business of providing active pharmaceuticals ingredients, eco-chemicals including antimicrobials for personal care and industrial applications, as well as water treatment solutions.

Kolon Life Science Headquarter Location

South Korea

Latest Kolon Life Science News

Regulator re-notifies 2019 Invossa recall

May 25, 2021

닫기 The controversy over the safety of Invossa-K, gene therapy for osteoarthritis by Kolon Life Science, has surfaced again after the drug regulator re-notified its 2019 order to recall and discard all Invossa products. The notification came amid the company’s ongoing legal battles to reverse the Ministry of Food and Drug Safety’s decision to nullify the Invossa permit. Life Science’s Invossa-K has drawn the pharmaceutical industry’s attention after the drug regulator re-notified the 2019 recall of Invossa. The ministry said it re-notified the recall because Kolon Life Science recently withdrew the lawsuit against the regulator’s order to recall and discard Invossa products. On Thursday, the ministry announced that it re-notified the recall and discard order on all products of Invossa-K as of May 14 on the regulator’s integrated drug information website. In the notice, the regulator said Invossa received approval even though the main ingredient of the second fluid was not cartilage-derived cells but kidney-derived cells. As Kolon manufactured and sold Invossa products that contained kidney-derived cells posing a risk to public health, the government had to recall the product, it said. In response, Kolon Life Science, “We had already completed the recall and discarded of Invossa a long time ago.” As pharmaceutical industry watchers closely followed the re-notification of the Invossa recall, the ministry hurried to clarify the details. The ministry revised the date of the recall order to July 9, 2019, explaining on the drug information website that the re-notification came after the company’s lawsuit withdrawal. “During the 2019 Invossa recall, Kolon Life Science filed a suit to stop the ministry recall order. A court recognized Kolon’s request, and we had to remove the recall order,” a ministry official said. “Recently, as Kolon withdrew its lawsuit for the recall nullification and notified the regulator on May 14, we resumed the 2019 order and re-notified it.” On April 29, Kolon Life Science said in a public filing that it canceled two administrative suits over approval for the phase-3 K&L Grade2 trial plan and the order to recall and discard Invossa, out of the three ongoing administrative lawsuits. However, it would continue to pursue the administrative suit to reverse the ministry’s decision to nullify the license of Invossa, Kolon Life Science said. In February, the Seoul Administrative Court turned down Kolon’s appeal for suspending the execution of the order to stop making and selling Invossa. Kolon Life Science filed an appeal in March and is proceeding with the lawsuit.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Kolon Life Science

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kolon Life Science is included in 1 Expert Collection, including Advanced Materials.

A

Advanced Materials

1,206 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.

Kolon Life Science Patents

Kolon Life Science has filed 4 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • Orthopedic surgical procedures
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/27/2016

5/11/2021

Molecular biology, Biotechnology, Genetics, Virology, Animal virology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/27/2016

00/00/0000

00/00/0000

00/00/0000

Grant Date

5/11/2021

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Biotechnology, Genetics, Virology, Animal virology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Kolon Life Science Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kolon Life Science Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.